Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENSURE-2: IMU-838 in Relapsing Multiple Sclerosis
NCT05201638Phase 3Active, not recruiting
- Sponsor
- Immunic Therapeutics
- Start
- Jan 2022
- Primary completion
- Nov 2026
- Countries
- 14
01
Overview
A Phase 3 trial of vidofludimus calcium in multiple sclerosis (MS), sponsored by Immunic Therapeutics. Started Jan 2022; status: active, not recruiting.
02
Drugs
vidofludimus calcium
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05201638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201638.